|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.185 SEK | -0.14% |
|
-0.21% | -18.63% |
| Apr. 23 | Synact Pharma AB Announces Changes in Nomination Committee Ahead of the 2024 Annual General Meeting | CI |
| Mar. 20 | Sweden's SynAct Pharma Names New CEO | MT |
SynAct Pharma AB reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was SEK 99.21 million compared to SEK 69.3 million a year ago. Basic loss per share from continuing operations was SEK 3.6 compared to SEK 2.68 a year ago.
Diluted loss per share from continuing operations was SEK 3.6 compared to SEK 2.68 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.63% | 27.76M | |
| +44.48% | 55.07B | |
| +44.08% | 40.22B | |
| -0.86% | 41.79B | |
| -7.59% | 28.17B | |
| +12.30% | 26.28B | |
| -21.83% | 18.93B | |
| +7.15% | 13.03B | |
| +29.40% | 12.26B | |
| +25.15% | 12.21B |
SYNACT PHARMA AB 